Lifecore Biomedical, Inc. LFCR
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -25.89% | 47.32% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -25.89% | 47.32% | |||
| Cost of Revenue | -16.28% | 17.94% | |||
| Gross Profit | -43.47% | 170.62% | |||
| SG&A Expenses | -20.98% | 26.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.04% | 20.31% | |||
| Operating Income | -134.83% | 183.56% | |||
| Income Before Tax | -552.75% | 58.94% | |||
| Income Tax Expenses | 121.74% | -46.51% | |||
| Earnings from Continuing Operations | -551.14% | 58.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -551.14% | 58.91% | |||
| EBIT | -134.83% | 183.56% | |||
| EBITDA | -70.17% | 766.93% | |||
| EPS Basic | -471.43% | 55.39% | |||
| Normalized Basic EPS | -548.14% | 54.14% | |||
| EPS Diluted | -471.43% | 55.39% | |||
| Normalized Diluted EPS | -548.14% | 54.14% | |||
| Average Basic Shares Outstanding | 0.72% | 0.26% | |||
| Average Diluted Shares Outstanding | 0.72% | 0.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||